Showing results (41-50 of 78) with videos related to
Sort By:
Pageof 8
Circulation. Cardiovascular Imaging|March 9, 2016
HIV-1-Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial EdemaNtobeko Ntusi, Eoin O'Dwyer, Lucy Dorrell, et al.Open Forum Infectious Diseases|November 28, 2015
Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell ResponsesSabine Kinloch-de Loes, Lucy Dorrell, Hongbing Yang, et al.The Journal of Infectious Diseases|June 20, 2012
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infectionHongbing Yang, Hao Wu, Gemma Hancock, et al.European Journal of Immunology|April 16, 2005
CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotypeGeraldine M A Gillespie, Susana Pinheiro, Mohammad Sayeid-Al-Jamee, et al.Journal of Virology|April 28, 2006
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccineLucy Dorrell, Hongbing Yang, Beatrice Ondondo, et al.Circulation|July 3, 2013
Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patientsCameron J Holloway, Ntobeko Ntusi, Joseph Suttie, et al.Journal of Virology|November 30, 2018
Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV ControllersMiriam Rosás-Umbert, Anuska Llano, Rocío Bellido, et al.Cell Reports|May 12, 2021
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responsesHongbing Yang, Anuska Llano, Samandhy Cedeño, et al.Vaccine|September 24, 2005
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteersInese Cebere, Lucy Dorrell, Helen McShane, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|July 13, 2016
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell ReceptorsHongbing Yang, Sandrine Buisson, Giovanna Bossi, et al.Pageof 8